Dimensional Fund Advisors Portfolio holdings
Dimensional Fund Advisors (DFA), founded in 1981 by David Booth and Rex Sinquefield and headquartered in Austin, Texas, is an investment management firm renowned for its evidence-based, low-cost approach to investing, grounded in academic research from Nobel laureates like Eugene Fama and Kenneth French. Managing hundreds of billions in assets, DFA focuses on systematic, passive strategies that tilt toward factors like small-cap, value, and profitability stocks, primarily through mutual funds and institutional portfolios rather than retail brokerage services. The firm’s philosophy eschews market timing and stock picking, instead emphasizing diversification and efficient market exposure, often requiring investors to access its funds through approved financial advisors. With a global presence and a reputation for disciplined, data-driven investing, DFA has carved a unique niche in the industry, blending academic rigor with practical application.
Top Buys
| 1 |
NVIDIA
NVDA
|
+$1.06B |
| 2 |
Apple
AAPL
|
+$625M |
| 3 |
UnitedHealth
UNH
|
+$201M |
| 4 |
Cisco
CSCO
|
+$192M |
| 5 |
Johnson & Johnson
JNJ
|
+$182M |
Top Sells
| 1 |
Meta Platforms (Facebook)
META
|
+$608M |
| 2 |
Broadcom
AVGO
|
+$240M |
| 3 |
United Rentals
URI
|
+$212M |
| 4 |
CRH
CRH
|
+$200M |
| 5 |
Pfizer
PFE
|
+$174M |
Sector Composition
| 1 | Technology | 18.69% |
| 2 | Financials | 17.09% |
| 3 | Industrials | 13.01% |
| 4 | Consumer Discretionary | 11.1% |
| 5 | Healthcare | 10.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
3001
Corbus Pharmaceuticals
CRBP
$121M
| $631K | ﹤0.01% |
16,075
-617
| -4% | -$24.2K |
|
3002
Sound Financial Bancorp
SFBC
$112M
| $630K | ﹤0.01% |
15,689
+316
| +2% | +$12.7K |
|
|
FNCB
3003
DELISTED
FNCB Bancorp Inc. Common Stock
FNCB
| $621K | ﹤0.01% |
102,330
| – | – |
|
3004
USCB Financial Holdings
USCB
$346M
| $617K | ﹤0.01% |
54,107
+10,545
| +24% | +$120K |
|
3005
Xoma
XOMA
$427M
| $614K | ﹤0.01% |
25,516
| – | – |
|
3006
EyePoint Pharmaceuticals
EYPT
$941M
| $612K | ﹤0.01% |
29,610
| – | – |
|
3007
SIFCO Industries
SIF
$43.8M
| $612K | ﹤0.01% |
192,377
| – | – |
|
3008
First Capital
FCAP
$145M
| $611K | ﹤0.01% |
21,074
+414
| +2% | +$12K |
|
3009
ATS Corp
ATS
$2.66B
| $605K | ﹤0.01% |
+17,945
| New | +$605K |
|
3010
Cassava Sciences
SAVA
$103M
| $602K | ﹤0.01% |
29,656
+12,319
| +71% | +$250K |
|
3011
Cumberland Pharmaceuticals
CPIX
$49.5M
| $601K | ﹤0.01% |
357,615
-8,319
| -2% | -$14K |
|
3012
Fossil Group
FOSL
$160M
| $600K | ﹤0.01% |
587,914
-268,163
| -31% | -$274K |
|
3013
United-Guardian
UG
$38.8M
| $600K | ﹤0.01% |
77,566
-7,572
| -9% | -$58.5K |
|
3014
Rafael Holdings
RFL
$47M
| $593K | ﹤0.01% |
349,867
-22,712
| -6% | -$38.5K |
|
3015
Nine Energy Service
NINE
$28.5M
| $593K | ﹤0.01% |
264,517
-20,904
| -7% | -$46.8K |
|
3016
XBiotech
XBIT
$83.5M
| $589K | ﹤0.01% |
72,475
| – | – |
|
3017
Janux Therapeutics
JANX
$1.49B
| $587K | ﹤0.01% |
+15,597
| New | +$587K |
|
3018
John Wiley & Sons Class B
WLYB
| $579K | ﹤0.01% |
15,247
-3,077
| -17% | -$117K |
|
3019
American Coastal Insurance
ACIC
$550M
| $575K | ﹤0.01% |
53,778
-7,726
| -13% | -$82.6K |
|
3020
CoreCard
CCRD
$214M
| $570K | ﹤0.01% |
51,561
| – | – |
|
3021
Alpha Pro Tech
APT
$51.2M
| $569K | ﹤0.01% |
91,236
+12,694
| +16% | +$79.2K |
|
3022
Shattuck Labs
STTK
$90.1M
| $569K | ﹤0.01% |
63,665
-10,002
| -14% | -$89.4K |
|
|
ACCS
3023
ACCESS Newswire Inc.
ACCS
$42.1M
| $568K | ﹤0.01% |
43,955
-8,146
| -16% | -$105K |
|
|
TGB
3024
Taseko Mines
TGB
$1.1B
| $568K | ﹤0.01% |
261,539
+1,171
| +0.4% | +$2.54K |
|
3025
Black Diamond Therapeutics
BDTX
$174M
| $566K | ﹤0.01% |
111,666
+1,054
| +1% | +$5.34K |
|